25Q4收入环比持续增长，在前三季度持续经营业务收入增速基础上仍保持了全年20%以上的增长（24Q4基数不 低），Non-IFRS归母净利率来看25Q4表现稳定，达到35.1%略低于25Q3。 #TIDES业务持续高增长，国内景气回暖有望带动利润率进一步提升 25年TIDES业务收入增速超90%，考虑到26年大单带动下Chemistry业务仍将维持快速增长、毛利率提升趋势，在海 外需求稳定恢复、国内即将迎来上游拐点背景下，26年利润端仍有超预期的潜力。 【持续推荐药明康德】稀缺的增长确定性与回调下来的好位置 公司已发布25年业绩预增公告，25年收入454.6亿元（+15.8%，其中持续经营业务收入增速21.4%）超过三季报公 司指引25年全年收入435-440亿元，持续经营业务收入增速为17-18%。 25Q4收入环比持续增长，在前三季度持续经营业务收入增速基础上仍保持了全年20%以上的增长（24Q4基数不 低），Non-IFRS归母净利率来看 【持续推荐药明康德】稀缺的增长确定性与回调下来的好位置 公司已发布25年业绩预增公告，25年收入454.6亿元（+15.8%，其中持续经营业务收入增速21.4%）超过 ...

Group 1 - The top three companies with the highest AH premium rates are Northeast Electric (00042) at 730.77%, Beijing Jingcheng Machinery Electric (00187) at 288.68%, and Sinopec Oilfield Service (01033) at 288.17% [1][2] - The bottom three companies with the lowest AH premium rates are CATL (03750) at -16.06%, WuXi AppTec (02359) at -7.28%, and China Merchants Bank (03968) at -4.68% [1][2] - The companies with the highest deviation values are Beijing Jingcheng Machinery Electric (00187) at 24.37%, Longpan Technology (02465) at 16.69%, and Cambridge Technology (06166) at 16.18% [1][3] Group 2 - The companies with the lowest deviation values are Northeast Electric (00042) at -85.40%, Junda Co., Ltd. (02865) at -56.63%, and Yangtze Optical Fibre and Cable (06869) at -52.47% [1][4] - The top ten AH stocks by premium rate include companies like Hongye Futures (03678) at 275.78% and Nanjing Panda Electronics (00553) at 237.14% [2] - The bottom ten AH stocks by premium rate include Weichai Power (02338) at -0.89% and Zijin Mining (02899) at 3.75% [2]

Core Viewpoint - Nomura's report indicates that WuXi AppTec's revenue is expected to grow by 9.2% year-on-year to 11.7 billion yuan in Q4 2025, with net profit increasing by 142% to 7.1 billion yuan [1] Financial Projections - For the fiscal year 2026, revenue is projected to grow by 16% year-on-year to 52.6 billion yuan, surpassing market expectations of 51.1 billion yuan due to strong performance in the chemical business [1] - Net profit for 2026 is expected to increase by 3% year-on-year to 19.6 billion yuan [1] Business Segment Performance - By business segment, revenue for TIDES and late-stage development and manufacturing is expected to grow by 55% and 10% year-on-year, reaching 17.1 billion yuan and 21.6 billion yuan respectively [1] - The growth in TIDES is supported by sustained demand and the company's large-scale functional production capacity of 100,000 liters [1] Target Price Adjustments - Nomura has raised the target price for WuXi AppTec's H-shares from 132.8 HKD to 157.07 HKD and for A-shares from 120.85 CNY to 142.93 CNY, maintaining a "Buy" rating [1]

Group 1 - The stock price of Reborn Biotech (06938.HK) increased by 13.65% [1] - WuXi Biologics (02269.HK) saw a rise of 4.83% in its stock price [1] - Baosai Tu-B (02315.HK) experienced a stock price increase of 3.88% [1] - WuXi AppTec (02359.HK) had a stock price growth of 3.15% [1]

Group 1 - The article highlights the top three companies with the highest AH premium rates: Northeast Electric (00042) at 831.03%, Beijing Jingcheng Machinery Electric (00187) at 291.45%, and Sinopec Oilfield Service (01033) at 288.17% [1] - The bottom three companies with the lowest AH premium rates are Contemporary Amperex Technology (03750) at -12.59%, WuXi AppTec (02359) at -4.58%, and China Merchants Bank (03968) at -4.48% [1] - The article provides a detailed ranking of the top ten and bottom ten AH stocks based on their premium rates and deviation values, indicating significant disparities in market valuations between H-shares and A-shares [1][2] Group 2 - The deviation values for the top three companies are Beijing Jingcheng Machinery Electric (00187) at 27.77%, Jinju Group (02009) at 19.35%, and Kai Sheng New Energy (01108) at 16.80% [1] - The bottom three companies with the most negative deviation values are Junda Co., Ltd. (02865) at -60.53%, Chenming Paper (01812) at -32.02%, and CNOOC Services (02883) at -31.42% [1][2] - The article emphasizes that the deviation value represents the difference between the current premium rate and the average premium rate over the past 30 days, providing insights into market trends [2]

Core Viewpoint - The report highlights the AH premium rates of various companies, indicating significant discrepancies between their H-shares and A-shares, with some companies showing extremely high premiums while others exhibit negative premiums [1]. Group 1: Top AH Premium Rates - Northeast Electric (00042) has the highest AH premium rate at 831.03%, with H-share priced at 0.290 HKD and A-share at 2.25 CNY [1]. - Sinopec Oilfield Service (01033) follows with a premium rate of 296.70%, H-share at 0.910 HKD and A-share at 3.01 CNY [1]. - Beijing Jingcheng Machinery Electric (00187) ranks third with a premium of 285.05%, H-share at 4.280 HKD and A-share at 13.76 CNY [1]. Group 2: Lowest AH Premium Rates - Contemporary Amperex Technology (03750) has the lowest AH premium rate at -13.27%, with H-share priced at 511.000 HKD and A-share at 370 CNY [1]. - China Merchants Bank (03968) shows a premium of -4.06%, H-share at 49.300 HKD and A-share at 39.49 CNY [1]. - WuXi AppTec (02359) has a premium of -2.14%, with H-share at 120.800 HKD and A-share at 98.7 CNY [1]. Group 3: Top Deviation Values - Jinju Group (02009) has the highest deviation value at 24.42%, with a premium of 212.05% [1]. - Beijing Jingcheng Machinery Electric (00187) has a deviation value of 21.92%, with a premium of 285.05% [1]. - Longpan Technology (02465) ranks third with a deviation value of 19.68%, and a premium of 101.01% [1]. Group 4: Lowest Deviation Values - JunDa Co., Ltd. (02865) has the lowest deviation value at -70.56%, with a premium of 176.15% [2]. - Changfei Optical Fiber (06869) follows with a deviation of -45.38%, and a premium of 105.94% [2]. - Chenming Paper (01812) has a deviation of -26.81%, with a premium of 190.80% [2].

Core Viewpoint - ByteDance's AI video generation model Seedance 2.0 has gained significant attention both domestically and internationally, leading to a surge in AI application themes in the A-share market [1][4]. Market Overview - On February 10, the A-share market exhibited a fluctuating trend with noticeable structural differentiation. AI application themes saw widespread increases, particularly in sectors such as short drama games, cultural media, online games, virtual humans, and cybersecurity, while the photovoltaic industry experienced a pullback [1]. - The Shanghai Composite Index closed at 4122.34, down 0.02%, and the Shenzhen Component Index closed at 14206.26, also down 0.02% [2]. Cultural Media Sector - The cultural media sector experienced a significant surge, with multiple stocks hitting the 20% limit up, including Readkey Culture, Jiecheng Co., Rongxin Culture, Light Media, and Chinese Online. Other stocks like Happiness Blue Sea rose over 10% [4][5]. - The cultural media index rose by 6.76%, indicating strong market performance [5]. AI Video Technology Impact - Seedance 2.0 is expected to lead the way in the short content field, such as AI comic dramas and short dramas, by significantly reducing production costs and shortening production cycles. This advancement is anticipated to drive industry capacity expansion [6]. - The model's capabilities include self-storyboarding, multi-modal references, audio-visual synchronization, and multi-camera narrative capabilities, which are expected to enhance video usability and lower production costs [6]. Gaming Sector Performance - The gaming sector also saw widespread gains on February 10, with stocks like Wento Holdings and Perfect World reaching their daily limits [8]. - The gaming index increased by 4.71%, reflecting positive market sentiment [9]. Regulatory Environment and Market Growth - In January 2026, 182 game licenses were issued, continuing a trend of normalized issuance since 2025, indicating regulatory support for the industry's healthy development. The gaming market's actual sales revenue is projected to reach 350.79 billion yuan in 2025, marking a 7.68% year-on-year growth [9][10]. - The gaming sector is expected to benefit from AI applications, with both established and new games leveraging AI to enhance user engagement and content creation [10]. Hong Kong Market Trends - The Hong Kong market mirrored the A-share surge, particularly in cultural media and innovative drug services, with notable gains in stocks like WuXi Biologics and WuXi AppTec [11].

Group 1 - The core viewpoint of the article highlights the significant rise in the stock prices of CRO (Contract Research Organization) concept stocks in the Hong Kong market on February 10 [1] Group 2 - Viatris (01873.HK) saw an increase of 6.14%, reaching HKD 2.42 [1] - WuXi Biologics (02269.HK) rose by 6.01%, with a stock price of HKD 40.54 [1] - Tigermed (03347.HK) experienced a 4.65% increase, trading at HKD 56.3 [1] - WuXi AppTec (02359.HK) grew by 4.31%, with shares priced at HKD 121 [1]

Group 1 - CRO concept stocks have shown significant gains, with Weiya Bio rising by 6.14% to HKD 2.42, WuXi Biologics increasing by 6.01% to HKD 40.54, Tigermed up by 4.65% to HKD 56.3, and WuXi AppTec rising by 4.31% to HKD 121 [1] - WuXi AppTec's net profit is expected to increase by 103% year-on-year in 2025, while Tigermed's net profit is projected to grow by 105-204% [1] - Global biopharmaceutical investment and financing data is expected to recover starting in 2025, with global and China year-on-year growth rates of 2.7% and 6.4% respectively, driven by a surge in innovative drug development [1] Group 2 - The report from Guotai Junan Securities indicates that as financing and business development (BD) recover, pharmaceutical companies are increasing their investment in clinical trials, leading to a resurgence in demand for clinical CRO, SMO, and registration services [1] - Debon Securities believes that the CXO and upstream research services primarily support the development and later production of innovative drugs, and expects both sectors to maintain a positive performance trend as innovative drug development heats up [1]

Group 1 - CRO concept stocks have shown significant gains, with companies like Viatris (01873) up 6.14% to HKD 2.42, WuXi Biologics (02269) up 6.01% to HKD 40.54, Tigermed (03347) up 4.65% to HKD 56.3, and WuXi AppTec (02359) up 4.31% to HKD 121 [1] - WuXi AppTec's net profit is expected to increase by 103% year-on-year in 2025, while Tigermed's is projected to rise by 105-204% [1] - Global biopharmaceutical investment and financing data is expected to recover starting in 2025, with global and China year-on-year growth rates of 2.7% and 6.4% respectively, driven by a surge in innovative drug development [1] Group 2 - The report from Guotai Junan Securities indicates that as financing and business development (BD) recover, pharmaceutical companies are increasing their investment in clinical trials, leading to a resurgence in demand for clinical CRO, SMO, and registration services [1] - Debon Securities believes that CXO and upstream research services primarily support the development and later production of innovative drugs, and expects both sectors to maintain a positive performance trend due to the booming innovative drug development [1]